Research Topics
| Ilya A LipkovichSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Early predictors of substantial weight gain in bipolar patients treated with olanzapineIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:316-20. 2006..Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation...- Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trialsIlya Lipkovich
Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, USA
Psychopharmacol Bull 42:23-39. 2009..These results confirm that cut-offs for weight gain during the first 4 weeks of treatment may be useful in evaluating SWG risk for an individual patient... - Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustmentsIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Drop Code 4133, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 25:381-6. 2005..Techniques used in this analysis may prove to be useful in assessing the relationship between dose change and safety and efficacy measures... 
Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approachIlya A Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Psychiatry Res 170:161-7. 2009..Early symptom response significantly improved the prediction of outcome, suggesting that early monitoring of treatment response may be useful in clinical practice...
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapyIlya A Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, USA
BMC Psychiatry 9:44. 2009..This post-hoc analysis evaluates the relationships among cognition, psychopathology, and psychosocial functioning in patients with schizophrenia at baseline and following sustained treatment with antipsychotic drugs...- Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorderIlya Lipkovich
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
BMC Psychiatry 8:78. 2008..We therefore conducted a post-hoc analysis of clinical trial data, examining early weight gain as a predictor of later substantial weight gain... - Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approachIlya A Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46221, USA
BMC Psychiatry 8:65. 2008..The objective of this exploratory analysis was to characterize response in bipolar disorder by identifying groups of patients with similar manic symptom response profiles... - Evaluating dose response from flexible dose clinical trialsIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis Indiana, USA
BMC Psychiatry 8:3. 2008..The true dose effect in flexible-dose clinical trials may be obscured and even reversed because dose and outcome are related... - Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbancesIlya Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46221, USA
J Geriatr Psychiatry Neurol 20:107-14. 2007..001) or placebo (P < .001). Weight gain in olanzapine-treated older patients with dementia and behavioral disturbances was significantly greater in individuals with a baseline body mass index of less than 25 kg/m2... - Subgroup identification based on differential effect search--a recursive partitioning method for establishing response to treatment in patient subpopulationsIlya Lipkovich
Eli Lilly and Company, Indianapolis, IN, USA
Stat Med 30:2601-21. 2011..We evaluate the operating characteristics of the procedure using a simulation study and illustrate the method with a clinical trial example... - Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapyI Lipkovich
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC 4133, Indianapolis, IN 46285, USA
J Psychiatr Res 41:305-10. 2007..To evaluate the relationship of dose decrease, symptom worsening, and baseline covariates on subsequent relapse during olanzapine treatment in patients with schizophrenia or schizoaffective disorder... - Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithiumJohn P Houston
Lilly Corporate Center, Lilly Research Laboratories, Drop Code 4133, Indianapolis, IN 46285, United States
J Psychiatr Res 41:616-21. 2007.... - Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approachYongming Qu
Eli Lilly and Company, Indianapolis, IN 46285, U S A
Stat Med 28:1402-14. 2009..Simulation shows that all adjusted estimators are much less biased than the naive estimator. Under certain conditions MIMP provides benefits (smaller bias and mean-squared error) compared with existing alternatives... - Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysisVirginia L Stauffer
Neuroscience, Lilly USA, LLC, Indianapolis, IN 46285, USA
BMC Psychiatry 9:12. 2009..Identification of patient subgroups with different degrees of susceptibility to the effect of weight mitigating agents during olanzapine treatment may aid clinicians in treatment decisions... - A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptomsBruce J Kinon
Eli Lilly and Company, Indianapolis, IN 46285, USA
J Clin Psychopharmacol 26:157-62. 2006..The objective of this study is to compare olanzapine with ziprasidone therapy in patients with schizophrenia or schizoaffective disorder and experiencing depressive symptoms... - Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trialsJoseph L Micca
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
Am J Geriatr Psychiatry 14:62-70. 2006..Risk of diabetes in these studies was not significantly associated with antipsychotic treatment group assignment... - Comparison of several imputation methods for missing baseline data in propensity scores analysis of binary outcomeBrenda J Crowe
Eli Lilly and Company, Indianapolis, IN, USA
Pharm Stat 9:269-79. 2010..Treatment Mean Imputation performed better than MI methods that did not include both the treatment and outcome in the imputer's model...